Pyronaridine is a naphthyridine derivative that has traditionally been used in China in the treatment of malaria. Its use has also been investigated in Africa and Thailand. A combination medication comprising pyronaridine phosphate and artesunate has been formulated to enhance patient compliance, minimize monotherapy usage, and mitigate the emergence of drug resistance. This combined treatment is designated for addressing acute uncomplicated infections instigated by Plasmodium vivax and Plasmodium falciparum in regions characterized by low transmission rates and confirmed artemisinin resistance. The World Health Organization (WHO) recommends artesunate-pyronaridine use in areas where alternative artemisinin-based combination therapies are demonstrating ineffectiveness.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Pyronaridine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.